{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:46Z","timestamp":1792696546510,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40265-014-0276-7","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T20:16:12Z","timestamp":1407960972000},"page":"1555-1558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Tavaborole: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"issue":"2 Suppl 1","key":"276_CR1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.12788\/j.sder.0016","volume":"32","author":"B Elewski","year":"2013","unstructured":"Elewski B, Pariser D, Rich P, et al. Current and emerging options in the treatment of onychomycosis. Semin Cutan Med Surg. 2013;32(2 Suppl 1):S9\u201312.","journal-title":"Semin Cutan Med Surg."},{"key":"276_CR2","unstructured":"Anacor Pharmaceuticals Inc. FDA approves Anacor Pharmaceuticals KERYDINTM (tavaborole) topical solution, 5\u00a0% for the treatment of onychomycosis of the toenails [media release]. 2014. http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=858211 ."},{"key":"276_CR3","unstructured":"Anacor Pharmaceuticals Inc. Tavaborole KERYDINTM (tavaborole): US prescribing information. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204427s000lbl.pdf . Accessed 24 Jul 2014."},{"key":"276_CR4","unstructured":"Anacor Pharmaceuticals Inc. Anacor regains worldwide rights to AN2690 from Merck. [media release]. 2010. http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=527619 ."},{"issue":"5832","key":"276_CR5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","volume":"316","author":"FL Rock","year":"2007","unstructured":"Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007;316(5832):1759\u201361.","journal-title":"Science."},{"key":"276_CR6","unstructured":"Sanders V, Baker S, Alley M. Microbiological activity of AN2690, a new antifungal agent in development for the topical treatment of onychomycosis [poster]. 2006. http:\/\/www.anacor.com\/pdf\/AAD_P1608.pdf . Accessed 6 Aug 2014."},{"issue":"10","key":"276_CR7","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/jps.20901","volume":"96","author":"X Hui","year":"2007","unstructured":"Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007;96(10):2622\u201331.","journal-title":"J Pharm Sci."},{"issue":"10","key":"276_CR8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2014.921158","volume":"15","author":"BE Elewski","year":"2014","unstructured":"Elewski BE, Tosti A. Tavaborole for the treatment of onychomycosis. Expert Opin Pharmacother. 2014;15(10):1439\u201348.","journal-title":"Expert Opin Pharmacother."},{"issue":"2 Suppl 2","key":"276_CR9","first-page":"129","volume":"56","author":"K Beutner","year":"2007","unstructured":"Beutner K, Sanders V, Hold K. An open-label, multiple-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5\u00a0% solution to all toenails of adult patients with moderate to severe onychomycosis. J Am Acad Dermatol. 2007;56(2 Suppl 2):129.","journal-title":"J Am Acad Dermatol."},{"key":"276_CR10","first-page":"S47","volume":"131","author":"J Dosik","year":"2011","unstructured":"Dosik J, Lastella P, Yavel R, et al. The pharmacokinetics of AN2690 after topical application in patients with onychomycosis. J Invest Dermatol. 2011;131:S47.","journal-title":"J Invest Dermatol."},{"key":"276_CR11","unstructured":"Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the treatment of onychomycosis: results from two phase 3 studies [poster]. In: 10th Annual High Risk Diabetic Foot Conference, Phoenix, 20\u201322 Nov 2013."},{"issue":"5 Suppl 1","key":"276_CR12","first-page":"AB92","volume":"70","author":"M Toledo Bahena","year":"2014","unstructured":"Toledo Bahena M, Gomez JB, Zane L, et al. Safety and efficacy of tavaborole (AN2690), a novel boron-based molecule, in 3 phase II trials for the topical treatment of toenail onychomycosis. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB92.","journal-title":"J Am Acad Dermatol."},{"key":"276_CR13","unstructured":"Zane L, Pollak R. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis [poster no. P1608]. In: 100th National American Podiatric Medical Association, Washington DC, 16\u201319 August 2012."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0276-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0276-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:38Z","timestamp":1559504498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0276-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":13,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0276-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}